Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

  1. Bertolotto, A.
  2. Arroyo, R.
  3. Celius, E.G.
  4. Comi, G.
  5. Havrdova, E.K.
  6. Honeycutt, W.D.
  7. Hunter, S.F.
  8. Izquierdo, G.
  9. Kornek, B.
  10. Miller, T.
  11. Mitsikostas, D.D.
  12. Singer, B.A.
  13. Ziemssen, T.
  14. Chung, L.
  15. Daizadeh, N.
  16. Afsar, S.
  17. Hashemi, L.
  18. Senior, P.
Aldizkaria:
Neurology and Therapy

ISSN: 2193-6536,  2193-8253

Argitalpen urtea: 2020

Alea: 9

Zenbakia: 2

Orrialdeak: 443-457

Mota: Artikulua

DOI: 10.1007/S40120-020-00191-7 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus